InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（3 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
3
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Prasad Suyash, Directeur Médical et Responsable de la R&D. Officer active across 2 companies, notably Taysha Gene Therapies, Inc.. Aggregated, 3 disclosures have been recorded. Breakdown: 0 buy · 3 sells. Total volume traded: €758k. Activity tracked since 29 June 2021. The latest transaction was filed on 5 July 2022 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Prasad Suyash
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
3,905 股@ US$3.510.9% 占其流量Common StockSEC:0001209191-22-041455:0
12,324 股@ US$3.810.0026% mcap3.1% 占其流量Common StockSEC:0001209191-22-040356:0
35,056 股@ US$23.7492.3% 占其流量Common StockSEC:0001209191-21-044563:0
3 条申报中的 3 条
About Prasad Suyash
Suyash Prasad is the Chief Medical Officer and Head of R&D at Taysha Gene Therapies, Inc. He is responsible for overseeing research and development initiatives for gene therapies. Suyash plays a key role in innovation and advancing treatments aimed at improving patient outcomes. His expertise in medicine and biotechnology is essential for advancing Taysha's mission in the field of gene therapies.
